We have previously shown that minimally oxidized LDL (MM-LDL) activated endothelial cells to increase their interaction with monocytes but not neutrophils, inducing monocyte but not neutrophil binding and synthesis of monocyte chemotactic protein-i and monocyte colony-stimulating factor (M-CSF). In the present studies we have examined the signaling pathways by which this monocyte-specific response is induced. Both induction of monocyte binding and mRNA levels for M-CSF by MM-LDL were not inhibited in protein kinase C-depleted endothelial cells. A number of our studies indicate that cAMP is the second messenger for the effects of MM-LDL cited above. Incubation of endothelial cells with MM-LDL caused a 173% increase in intracellular cAMP levels. Agents which increased cAMP levels, including cholera toxin, pertussis toxin, dibutyryl cAMP, and isoproterenol mimicked the actions of MM-LDL. Agents which elevated cAMP were also shown to activate NFKB, suggesting a role for this transcription factor in activation of monocyte-endothelial interactions. Although endothelial leukocyte adhesion molecule (ELAM) mRNA synthesis can be regulated by NFKB, ELAM was not expressed and ELAM mRNA was only slightly elevated in response to MM-LDL. We present evidence that induction of neutrophil binding by LPS is actually suppressed by agents that elevated cAMP levels. (J. Clin. Invest. 1993. 92:471-478.)
Introduction
Activation of endothelial cells to synthesize binding molecules and chemotactic factors has been shown to elicit increased interaction with leukocytes (1) (2) (3) . An important early event in the initiation of atherosclerosis is the increased interaction of monocytes with endothelial cells lining the vessel wall (4) . In animals fed a high cholesterol diet, monocytes have been shown to bind more avidly to the endothelium, transmigrate through endothelial cell junctions, and enter the intimal space where they mature and form macrophages (5) . These macrophages accumulate lipids and contribute to the formation of the fatty streak.
Since oxidized lipids have been found in fatty streak lesions (6) and experiments with antioxidants have shown reduced lesion formation (7) , it is likely that these lipids play an important role in atherogenesis. Our group has shown that treatment of endothelial cells with minimally oxidized (modified) LDL (MM-LDL)' but not native LDL caused an increase in monocyte but not neutrophil binding and an increase in the production of monocyte chemotactic protein-I (MCP-1) and monocyte colony-stimulating factor (M-CSF) mRNA and protein (8) (9) (10) . However no neutrophil chemotactic factor could be detected ( 11) . In vivo studies showed that injection of MM-LDL but not highly oxidized LDL into mice induced increases in mRNA for MCP-1 and M-CSF (12) . Increased levels of mRNA for MCP-1 and M-CSF have been found in human fatty streak lesions ( 13, 14) . MCP-1 is a highly active monocyte chemotactic factor (15) . Proliferation and survival of monocytes and macrophages in the lesion may be supported by the local production of M-CSF ( 14) . Among the inflammatory mediators that have been tested, including LPS, thrombin, IL-1, and TNF (16-19), MM-LDL is the only one shown to induce monocyte but not neutrophil interaction with the endothelium. Understanding ofthe signaling molecules involved in the actions of MM-LDL is important since they also may be involved in other chronic inflammatory processes in vivo, characterized predominantly by monocytic infiltration.
To elucidate the mechanism of action of MM-LDL, we explored the signaling pathways by which it activates the endothelium. Two major second messengers that have been extensively studied are protein kinase C (PKC) and cAMP. The activation of both pathways in whole cells is mainly receptor mediated (20, 21) . PKC is a family of closely related proteins that differ in substrate specificity, co-factor dependency, and tissue distribution (21). It exists in an inactive form in the cytoplasm of cells and is generally activated in the presence of calcium and diacylglycerol. Phorbol esters such as phorbol myristate acetate (PMA) are known to induce cellular responses by directly activating PKC (21 ). Agonist-induced cellular responses caused by PKC activation are down-regulated by pretreatment of cells with phorbol esters for 24-48 h (21 ). Regulation of the activity of adenylate cyclase and/or cAMP phosphodiesterase determines the levels of intracellular cAMP (20) and, consequently, the activity of cAMP-dependent protein kinase (PKA) (22) . The activity of adenylate cyclase is regulated by excitatory (G.) and inhibitory (G1) G proteins (20) . The role of G proteins in mediating cellular responses to stimulators has been extensively reviewed (23, 24) . Cholera toxin (CT) activates Gs by ADP-ribosylating its alpha subunit, thus inhibiting its GTPase activity (25) . Pertussis toxin (PT) has been shown to inhibit Gi by ADP-ribosylation and to potentiate the effect of the stimulatory arm of the adenylate cyclase system (25) . Many physiological agonists act via cell surface receptors to alter adenylate cyclase activity; isoproterenol (IP), a beta adrenergic receptor agonist, has been shown to elevate cAMP levels in endothelial cells by activating Gs (26) .
In addition, purified PKC and isolated preparations of adenylate cyclase have been shown to be activated by certain native and oxidized fatty acids as well as products of lipid peroxidation (27) (28) (29) , which may be present in MM-LDL. Also it has been reported that alteration of membrane physical properties by changing its lipid composition affects adenylate cyclase activity (30) .
Activation of NFKB has been associated with gene expression in response to increased PKC or PKA activity (31, 32) . This transcription factor exists as a cytosolic dimer bound to an inhibitory molecule, IKB (33) . Activation of NFkB leads to its dissociation from IKB and its translocation to the nucleus where it binds to sequence-specific regulatory regions ofseveral genes. We examined the ability of MM-LDL to activate NFKB which may be involved in transcriptional regulation of genes by MM-LDL.
Methods
Cell preparation. Rabbit aortic endothelial cells (RAEC) at passages 9-17 and human aortic endothelial cells ( 11) or human aortic valve cells (kindly provided by Dr. Thomas Drake, UCLA School of Medicine) at passages 4-7 were used. For these studies, human monocytes were obtained by a modification of the Recalde method as described previously (8) . The human neutrophil cell line HL60 (American Type Culture Collection, Rockville, MD) was used as a source ofneutrophillike cells.
Leukocyte adhesion assay. For adhesion studies, endothelial cells were cultured in gelatin-coated 48-well dishes, in DME containing 15% calfserum (CS), 5 ,4g/ml endothelial cell growth supplement (ECGS), and 8 ,g/ml heparin (Sigma Chemical Co., St. Louis, MO). When confluent monolayers were formed, medium was changed to DME containing 10% CS without ECGS and heparin 24 h before the experiment. This medium was then removed and agonists added to cells in DME with 5% CS. The gradual lowering of the serum concentration minimized the basal levels of leukocyte binding to the endothelial monolayer. The concentration ofLPS in medium containing each agonist was < 50 pg/ml as determined by chromogenic assay. This level of LPS when present in LDL is 50-fold less than required to induce monocyte binding (data not shown). After (36, 37) , and malondialdehyde (MDA)-LDL (38) were made according to the previously published methods. LDL was minimally oxidized by iron and highly oxidized by copper, giving 2 and 10 nmol of thiobarbituric acidreactive substances per mg of cholesterol after dialysis, respectively.
Northern analysis. Endothelial cells were incubated at 370C for 4 h with or without agonist in DME containing 5% CS. Total RNA was isolated from cells using guanidine thiocyanate/phenol method (39).
10 ,gg of RNA was denatured at 650C for 10 min in 2.2 M formaldehyde and 50% deionized formamide and was electrophoresed through 1% agarose gel containing 2.2 M formaldehyde. RNA was transblotted to a nylon membrane (Hybond-N; Amersham Corp., Arlington Heights, IL) and cross-linked by ultraviolet light. The blot was prehybridized at 65°C for 2 h in 0.15 M Na2HPO4, 0.25 M NaH2PO4, 1 mM EDTA, 7% SDS, and 1% BSA, pH 7.0, and hybridized in the same buffer at 65°C overnight with 32P-labeled DNA probes for alpha tubulin, MCP-1 (9), M-CSF ( 10), or endothelial leukocyte adhesion molecule (ELAM) (kindly provided by Dr. Brian Seed, Harvard Medical School, Boston, MA). After hybridization, the blot was washed twice at room temperature in 2X SSC/0.1% SDS, and twice at 650C in 0.5x SSC/0. 1% SDS, for 20 min each, and exposed to x-ray film at -70°C. The extent of induction was determined by densitometric scanning.
cAMP measurement. For measuring cAMP levels, RAEC were cultured in 60-mm dishes and the cells were pretreated for 10 min with 0.5 mM 3-isobutyl-1-methylxanthine (IBMX, Calbiochem Corp., La Jolla, CA), an inhibitor of cAMP phosphodiesterase, in DME containing 5% CS. Agonists were then added and cells collected at several time points after being rinsed twice with PBS containing 4mM EDTA (also an inhibitor of cAMP phosphodiesterase) and scraped into the same buffer. The cell pellet after centrifugation was resuspended in 100 l1 of boiling water containing 4 mM EDTA. The suspension was sonicated, heated 3 min in a boiling water bath, and microcentrifuged for 2 min at high speed to spin out the coagulated proteins. The supernatant was used to determine cAMP levels.
Electrophoretic mobility shift assay. RAEC were cultured in 100-mm dishes. Approximately 107 cells were used per condition. After treatment with agonist, the cells were rinsed twice with ice-cold PBS and scraped into ice-cold PBS. The pellet was frozen in a dry ice/ethanol bath and stored at -70°C. Nuclear extracts were prepared according to the method described by Osborn et al. (40) .
Electrophoretic mobility shift assay was performed using 6% nondenaturing polyacrylamide gel according to the protocol provided in NFKB DNA binding protein detection system from Gibco-Bethesda Research Laboratories (Gaithersburg, MD). The double-stranded oligonucleotide supplied is a 40 mer containing a tandem repeat of the consensus sequence for NFKB DNA binding site, -GGGGACTTTCC-.
Results
To facilitate our studies, a new method of producing MM-LDL has been developed that is a modification of the procedure of Sparrow et al. (34) involving treatment of LDL with SLO and PLA2. This method has several advantages compared with our previous method of long-term storage at 4°C. The new method takes several days as compared with 6-12 mo, and LDL from 20 consecutive donors treated in this manner yielded biologically active MM-LDL. This enzymatic modification produced a low level of oxidation of LDL resulting in only a two-to threefold increase in conjugated dienes, an increase similar to that seen after cold storage. Like LDL that was minimally oxidized by storage, LDL oxidized by lipoxygenase and PLA2 caused an induction ofmonocyte but not neutrophil binding to RAEC treated for 4 h (Fig. 1) . In addition, such MM-LDL preparations induced the synthesis of mRNA for MCP-l and M-CSF, whereas native LDL did not cause such induction (Fig. 2 A) .
Characterization ofsecond messengers. We initially examined the role of PKC in mediating the effects of MM-LDL. It has been reported that chronic incubation ofcells with phorbol esters depletes the cellular content of PKCa and -fl, which have been shown to be the most prevalent forms in endothelial cells (41.) . Treatment of RAEC for 4 h with 10-40 nM PMA caused a strong induction ofmonocyte binding that was significantly down-regulated by a 48-h pretreatment with 10 nm PMA (Fig. 3 A) . This pretreatment did not down-regulate the binding induced by MM-LDL (Fig. 3 A) but markedly downregulated PKC activity in the pretreated cells (data not shown). Similarly, PMA pretreatment also did not inhibit the induction of mRNA levels for M-CSF by MM-LDL whereas induction by PMA was inhibited significantly (Fig. 3 B) . Although the MM-LDL-induced increase in M-CSF mRNA was lower than that induced by PMA, similar findings were obtained in three out of three experiments. These results suggested that PKC is not the second messenger involved in mediating the induction of monocyte binding and increase of M-CSF mRNA by MM-LDL. We investigated the role of cAMP in the MM-LDL-induced cellular responses. Incubation of RAEC with MM-LDL resulted in a 40 and 173% elevation of intracellular cAMP levels after 10 min and 2 h of treatment, respectively. CT and PT both induced similar cellular responses as MM-LDL. Incubation of RAEC with CT for 2 h and with PT for 1 h increased cAMP levels 100 and 200%, respectively (Table I ). Both CT and PT treatment of RAEC for 4 h caused a concentration-dependent induction of monocyte but not HL60 binding, with maximum responses at 400 ng/ml of CT and 30 ng/ml of PT (Fig. 1) . Both monocyte and HL60 binding were induced by LPS 10-and 20-fold, respectively (Fig. 1) . There was no additive effect of CT + MM-LDL (p = 0.4579, n = 6) or PT + MM-LDL (p = 0.3307, n = 6) compared with each toxin alone, even though maximal monocyte binding had not been obtained (as seen in LPS-treated cells). This lack of additivity suggests that MM-LDL, CT, and PT may act via similar signaling pathways. The results from CT and PT studies strongly suggest the involvement of adenylate cyclase and intracellular cAMP levels in the specific induction of monocyte binding to endothelial cells.
Further evidence that increased cAMP levels are responsible for the effects ofMM-LDL on induction ofmonocyte binding was suggested by the fact that pretreatment ofcells with 0.2 mM IBMX, a cAMP phosphodiesterase inhibitor, for 10 min before MM-LDL treatment increased monocyte binding to to deplete the cellular content of PKC, cells were first pretreated with 10 nM PMA in DME containing 10% CS for 48 h, indicated as (P/), followed by 4-h treatment with a second agonist as described above. P/O indicates 48 h pretreatment with 10 nM PMA with no further treatments. After this incubation, monocyte adhesion assay was performed as described in the legend of Fig. 1 The increased cAMP level observed after incubation of cells with MM-LDL produced by enzymatic modification was associated with the ability of this lipoprotein to induce monocyte but not HL60 binding. Iron-oxidized LDL, which has similar effects to MM-LDL made enzymatically, also increased cAMP levels and monocyte but not HL60 binding (Table I) . By contrast, incubation ofRAEC for 2 h with MDA-LDL ( 125 Mg/ml), copper-oxidized LDL (highly oxidized, 125 ,ug/ml), or lysophosphatidylcholine (LPC, 100 MM) decreased cAMP levels and did not induce either monocyte or HL60 binding (Table I) .
The possible involvement of cAMP elevation in the induction of mRNA for MCP-l and M-CSF by MM-LDL was also tested. Like MM-LDL, CT treatment of endothelial cells increased message for both MCP-l and M-CSF twenty-and fourfold, respectively (Fig. 2 B) , as determined by densitometric scanning. Incubation of RAEC with 1 mM dbcAMP for 4 h also caused a 10-fold increase in MCP-1 and a 3-fold increase in M-CSF mRNA levels as determined by densitometric scanning (Fig. 2 C) . In (Fig. 4 B) .
Why neutrophil binding is not increased by MM-LDL. ELAM is the major neutrophil-binding molecule on endothelial cell (42) . Treatment ofendothelial cells with MM-LDL did not increase surface expression of ELAM whereas LPS increased expression fourfold (Fig. 5 A) . MM-LDL in contrast to LPS caused only a minimal increase in ELAM mRNA levels, whereas both agents caused a major elevation of MCP-I mRNA (Fig. 5 B) . We found that induction ofneutrophil binding was actually inhibited by agents that elevate cAMP levels, Figure 4 . NFKB activation by MM-LDL or CT. (A) RAEC were treated for 2 h at 37°C with no additives (C), MM-LDL 125 'sg/ml (M), native LDL 125 ,g/ml (NL), or LPS 3 ng/ml (L). Electrophoretic mobility shift assay was performed using nuclear extracts of these cells following incubation with 32P-labeled sequence-specific oligonucleotide in the absence or presence (*) of unlabeled competitor oligonucleotide. (B) RAEC were treated with LPS (L), cholera toxin (CT), no additives (C), or MM-LDL (M) under similar conditions as in A. All experiments on activation of NFKB were performed on cells that had been tested for responsiveness to the agents used in adhesion and mRNA studies. such as CT. Incubation of RAEC with 3 ng/ml LPS for 4 h increased HL60 and monocyte binding to endothelial cells 13-and 9-fold, respectively (Fig. 6) . Incubation ofendothelial cells with 400 ng/ml CT and 0.5 mM IBMX for 2 h followed by 4 h of incubation with 3 ng/ml LPS significantly inhibited the induction of HL60 but not monocyte binding by LPS (Fig. 6 ). Such inhibition of the induction of HL60 and not monocyte binding by LPS was also seen after pretreatment ofendothelial cells with MM-LDL (Fig. 6) . Discussion
Exposure of endothelial cells to MM-LDL leads to increased monocyte but not neutrophil binding ( Fig. 1 ) and mRNA levels for MCP-l and M-CSF (Fig. 2 A) . Since the pattern of leukocyte binding and mRNA induction by MM-LDL is distinct from that of other inflammatory agents, we suspected the signaling pathways might be different. A number of studies have concluded that PKC plays a role in the signal transduction pathways initiated by thrombin, TNF-a, IL-1, and LPS (9, 16) . PMA pretreatment of endothelial cells, which has been shown to deplete the cellular content ofPKC (43), down-regulated the monocyte binding induced by PMA (Fig. 3 A) but did not inhibit the MM-LDL-induced monocyte binding or the MM-LDL-mediated increase in M-CSF mRNA (Fig. 3 B) , supporting the conclusion that PKC is not involved in these cellular responses. Furthermore, it has been previously shown that, in fibroblasts, the increase of mRNA levels for JE, the murine homologue of MCP-l gene (44) , by MM-LDL is PKC independent.
Another second messenger that mediates agonist-induced cellular responses is cAMP. It has been reported that cAMP levels mediate endothelial barrier properties (45) , as well as endothelium-dependent relaxations in response to thrombin, serotonin, and UK 14304 (a selective a2-adrenergic receptor agonist) (46) . Ofrelevance to the present report is the observation by Sung et al. (26) (Table I ). The responses induced by CT and PT, both ofwhich caused elevation ofcAMP levels (Table I) , and dbcAMP itself were similar to those induced by MM-LDL. These responses included increased monocyte but not HL60 binding (Fig. 1) , and increased levels of mRNA for MCP-l and M-CSF (Fig. 2) (8) and LPC (current study) are not responsible for the effects of MM-LDL on endothelial cells after 4 h of treatment. Our past and ongoing studies suggest that the active lipid responsible for the effects seen at 4 h is an oxidized phospholipid (8) . Previous reports showed that treatment of RAEC with levels of LPC used by us caused only a modest ( 1.4-fold) increase in monocyte binding (compared with the 4-10-fold induction seen with MM-LDL) and that the major effect ofLPC was seen after 24 h (48). Our previous studies have shown that effects of MM-LDL may continue to act up to 48 h (8), and it is clearly possible that different lipids, such as LPC, or lipoxygenase products, such as oxidized fatty acids, as reported by others to be active in monocytes (49) , may be responsible for the prolonged activation.
Since an NFKB binding site is present in the promoter region of JE (50) and M-CSF genes (50a), and cAMP has been suggested to play a role in NFKB activation ( 51 ), we suspected that NFKB may also be associated with MM-LDL regulation of gene transcription. Our results indicate that treatment ofendothelial cells with MM-LDL or CT causes activation of NFKB, whereas native LDL does not lead to such activation (Fig. 4, A  and B ). This suggests that NFKB activation is associated with the induction of cellular responses to increased intracellular cAMP levels. Our investigations have shown, however, that not all genes with NFKB binding site in their promoter region are induced by MM-LDL; mRNA levels of ELAM (52) were only minimally induced (Fig. 5 B) . We have further shown that increased cAMP levels induced by MM-LDL or CT inhibited the induction of neutrophil and not monocyte binding by LPS (Fig. 6) . Similarly, dibutyryl cAMP and forskolin suppression of LPS-induced TNF-a gene expression has been previously reported (53) . Pober et al. (54) reported that increased cAMP levels in forskolin-treated human umbilical vein endothelial cells inhibited TNF-induced ELAM expression. Our results also support the observation by Montgomery et al. (55) that NFKB is associated with but is not sufficient for ELAM message induction. We suggest that the MM-LDL-induced increase in cAMP levels inhibits ELAM expression.
It is evident from our observations that the increased monocyte binding induced by MM-LDL is independent of ELAM since MM-LDL did not increase ELAM expression (Fig. 5 A) . We have also ruled out VCAM and ICAM in contributing to the increased monocyte binding seen after 4 h incubation of endothelial cells with MM-LDL (56 
